PACLITAXEL FOR INJECTION 6 MG
PACLITAXEL : 6 MG · DIN 02244372 · BIOLYSE PHARMA CORPORATION
Health Canada status: MARKETED
What is PACLITAXEL FOR INJECTION?
PACLITAXEL FOR INJECTION 6 MG contains PACLITAXEL : 6 MG. It is listed in the Health Canada Drug Product Database under DIN 02244372, held by BIOLYSE PHARMA CORPORATION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 16-Jun-2003. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PACLITAXEL FOR INJECTION used for?
PACLITAXEL FOR INJECTION (paclitaxel) is indicated for the second-line treatment of advanced metastatic breast cancer resistant to the usual treatments, and for the first-line treatment of metastatic or locally advanced non-small cell lung cancer not subject to curative treatment by radiotherapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02244372 |
|---|---|
| Brand name | PACLITAXEL FOR INJECTION |
| Generic / active ingredient | PACLITAXEL : 6 MG |
| Manufacturer | BIOLYSE PHARMA CORPORATION |
| Strength | 6 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01CD01 PACLITAXEL |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Jun-2003 |
| Original market date | 2001-10-31 00:00:00 |
How is it stored and handled?
Unopened vials of Paclitaxel for Injection concentrate are stable until the date indicated on the package when stored between 2°C to 25°C in its original package. Do not freeze. The infusion must be initiated within 24 hours of reconstitution. The 50 mL bulk vial should be used within 8 hours after initial entry. The pH of Paclitaxel for Injection diluted in 0.9% Sodium Chloride Injection or 5% Dextrose Injection to a final concentration of 0.3 to 1.2 mg/mL remained within the range of 4.5 to 5.0 within a 24 hour period. The solutions are physically and chemically stable for up to 24 hours at ambient temperature (15° to 30º C).
How is it supplied?
Single dose vials of 5 mL, 16.7 mL and 25 mL and pharmacy bulk vials of 50 mL containing respectively 30 mg, 100 mg, 150 mg and 300 mg paclitaxel at a concentration of 6mg/mL.
Is PACLITAXEL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by ACCORD HEALTHCARE INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01CD01 PACLITAXEL. 5 of 19 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ABRAXANE FOR INJECTABLE SUSPENSION | 100 MG | POWDER FOR SUSPENSION | BRISTOL-MYERS SQUIBB CANADA | MARKETED | DIN 02281066 |
| PACLITAXEL INJECTION USP | 6 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02320150 |
| PACLITAXEL INJECTION USP | 6 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02391465 |
| PACLITAXEL POWDER FOR INJECTABLE SUSPENSION NANOPARTICLE, ALBUMIN-BOUND PACLITAXEL | 100 MG | POWDER FOR SUSPENSION | PANACEA BIOTEC PHARMA LIMITED | MARKETED | DIN 02496097 |
| AJ-PACLITAXEL | 6 MG | SOLUTION | AGILA JAMP CANADA INC | CANCELLED PRE MARKET | DIN 02409712 |
| APO-PACLITAXEL INJECTABLE | 6 MG | SOLUTION | APOTEX INC | DORMANT | DIN 02248844 |
| PACLITAXEL | 6 MG | LIQUID | IVAX PHARMACEUTICALS INCORPORATED | CANCELLED PRE MARKET | DIN 02241314 |
| PACLITAXEL FOR INJECTION | 6 MG | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02296624 |
| PACLITAXEL FOR INJECTION | 6 MG | SOLUTION | TEVA CANADA LIMITED | APPROVED | DIN 02285363 |
| PACLITAXEL FOR INJECTION USP | 6 MG | SOLUTION | STERIMAX INC | DORMANT | DIN 02320010 |
Who else supplies PACLITAXEL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PACLITAXEL appears in 289 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.